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23.4%, ranging from 4% to 100%. Complete revascularization
(SRI¼100%) was achieved in 64.3% of patients, SRI¼ 50-99% in 472
patients (25.5%), and SRI <50% in 189 patients (10.2%). The 2-year
rates of mortality (0.4%, 1.9%, and 2.7%, p¼0.001) and MACE (6.0%,
11.4%, and 10.1%, p<0.001) were higher in patients with lower SRI.
By ROC analysis, an SRI cut-off of 85% showed the best prognostic
accuracy for 2-year mortality. A SRI of 85% had similar low all-
cause death and cardiac death rates when compared to complete
(SRI¼100%) revascularization (Figure). By multivariable analysis,
SRI was a strong predictor of 2-year mortality (HR: 4.20, 95% CI:
1.46-12.08, p¼0.008) and 2-year MACE (HR: 1.59, 95% CI: 1.14-2.23,
p¼0.007).
CONCLUSIONS In patients with complex CAD undergoing EES-PCI,
the SRI was identiﬁed as a strong predictor of 2-years mortality and
MACE. Given its correlation with mortality, the SRI may be useful in
assessing the degree of revascularization after PCI, with SRI 85% as a
reasonable goal.
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BACKGROUND Recurrent chest pain after successful percutaneous
coronary intervention (PCI) is the main trigger of repeat assessment
and resource utilization. PCI of bifurcated target lesions are often
complex and bear a higher risk of adverse events and chest pain.
METHODS To compare 2-year clinical outcome and patient-reported
chest pain of patients with bifurcated vs. non-bifurcated lesions, we
assessed data of the DUTCH PEERS randomized trial (clinicaltrials.gov
NCT01331707), in which 1,811 all-comers were treated with zotar-
olimus-eluting Resolute Integrity (Medtronic) or everolimus-eluting
Promus Element (Boston Scientiﬁc) stents. Among 465 patients with
bifurcated lesions, we also compared the outcome of patients withtrue bifurcation lesions (i.e. lesions with side-branch involvement) vs.
non-true bifurcation lesion. The primary endpoint target lesion failure
(TLF) is a composite of cardiac death, target vessel myocardial
infarction (MI), and target lesion revascularization.
RESULTS Clinical follow-up was available in 1,810 patients (99.9%).
TLF was similar in patients with and without bifurcated lesions
(8.2% vs. 6.9%, p¼0.37). Target vessel MI was more common in pa-
tients with bifurcated lesions, however, after multivariate analysis
with use of a propensity score, this relation turned out to be not
statistically signiﬁcant (HR 1.40, 95%CI 0.71-2.76, p¼0.34). There was
no difference in TLF between patients treated for true vs. non-true
bifurcation lesions (8.9% vs. 7.8%, p¼0.70). At 1 and 2-year follow-
up, 88.0% and 88.1% of patients with bifurcated lesions and 87.7%
and 87.8% of patients with non-bifurcated lesions were free from
clinically relevant chest pain (p¼0.89 and 0.87, respectively). Be-
tween patients with true vs. non-true bifurcation lesions, no differ-
ence in patient-reported chest pain at 1 and 2-year follow-up was
observed (86.5% vs. 88.5%, p¼0.54, and 90.2% vs. 86.7%, p¼0.30,
respectively).
CONCLUSIONS The rates of chest pain were low and similar in pa-
tients with bifurcated versus non-bifurcated target lesions, who
showed favorable clinical outcomes at 1 and 2-year follow-up after
treatment with contemporary ﬂexible drug-eluting stents.
CATEGORIES CORONARY: Complex and Higher Risk Procedures for
Indicated Patients (CHIP)
KEYWORDS Bifurcation lesion, Drug-eluting stent, PCI - Percuta-
noeus Coronary InterventionTCT-20
Use of a Percutaneous Left Ventricular Assist Device for High Risk
Percutaneous Coronary Interventions. Clinical Trial versus Real World
Experience
Mauricio G. Cohen,1 Ray V. Matthews,2 Brij Maini,3 Simon Dixon,4
George W. Vetrovec,5 David H. Wohns,6 Igor F. Palacios,7
Jeffrey Popma,8 E. Magnus Ohman,9 Theodore Schreiber,10
William W. O’Neill11
1University of Miami MIller School of Medicine, Miami, FL; 2University
of Southern California, Los Angeles, CA; 3PinnacleHealth
Cardiovascular Institute, Wormleysburg, PA; 4Beaumont Hospital,
Royal Oak, United States; 5Virginia Commonwealth University,
Richmond, United States; 6Frederik Meijer Heart & Vascular Institute /
Spectrum Health, Grand Rapids, MI; 7Massachusetts General Hospital,
Boston, United States; 8Beth Israel Deaconess Medical Center, Boston,
MA; 9Duke University Medical Center, Durham, USA; 10Detroit Medical
Center Cardiovascular Institute, Detroit, MI; 11Henry Ford Hospital,
Detroit, United States
BACKGROUND High-risk percutaneous coronary intervention (PCI)
supported by percutaneous left ventricular assist devices offers a
treatment option for patients with severe symptoms, complex and
extensive coronary artery disease (CAD), and multiple comorbidities.
The extrapolation from clinical trial to real-world practice has
inherent uncertainties. We compared the characteristics, procedures,
and outcomes of high-risk PCI supported by a microaxial pump
(Impella 2.5) in a multicenter registry versus the randomized PRO-
TECT II trial (NCT00562016).
METHODS The USpella registry is an observational multicenter
voluntary registry of lmpella technology in 47 sites in the United
States and 2 sites in Canada. A total of 637 patients undergoing high-
risk PCI supported by Impella 2.5 between 6/2007 and 9/2013 were
included in this analysis. Of them, 339 patients would have met
enrollment criteria for the PROTECT II trial. Baseline variables, pro-
cedural characteristics, and in-hospital outcomes of these registry
patients were compared with 216 patients treated in the Impella arm
of the PROTECT II trial. All events were centrally adjudicated by an
independent clinical events committee.
RESULTS Compared to the clinical trial, registry patients were older
(7011.5 vs. 67.511.0 years), more likely to have chronic kidney
disease (30% vs. 22.7%), prior myocardial infarction (69.3% vs.
56.5%), prior by-pass surgery (39.4% vs. 30.2%), and had similar
prevalence of diabetes, peripheral vascular disease, and prior stroke.
Registry patients had more extensive CAD (2.2 vs. 1.8 diseased ves-
sels), and had a similar STS predicted risk of mortality (6.06.0 vs.
5.86.0, p¼0.64). Left ventricular ejection fraction was 23.46.3%
and 21.67.7%, in the registry and clinical trial, respectively
(p¼0.004). Use of rotational atherectomy was similar (16.4% vs.
14.8%, p¼0.63), but the number of passes per lesion was signiﬁcantly
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discharge, registry patients experienced a 42% reduction in NYHA
class III-IV symptoms. In-hospital mortality was numerically lower
among registry patients (2.7% vs. 4.6, p¼0.27). Need for blood
transfusions were similar in registry and clinical trial patients (9.1%
vs. 12.5%, p¼0.21). There were no differences in the occurrence of
other complications such as acute kidney failure, vascular injury or
ventricular arrhythmias.
CONCLUSIONS USpella provides a real world and contemporary
estimation of the type of procedures and outcomes of high-risk pa-
tients undergoing PCI supported by Impella 2.5. Despite the higher
risk of registry patients, clinical outcomes appeared to be favorable
and consistent compared with the randomized trial.
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BACKGROUND We sought to describe contemporary guidewire utili-
zation for antegrade wire escalation during chronic total occlusion
(CTO) percutaneous coronary intervention (PCI).
METHODS We examined guidewire and microcatheter utilization
during antegrade wire escalation attempts among 1097 CTO PCIs
performed at 13 experienced US centers between May 2012 and April
2015 using the hybrid approach.
RESULTS Mean age was 65  9.8 years, 83.2% of the patients were
men and 33.3% had prior coronary bypass graft surgery. Technical and
procedural success was 90.6% and 87.6%, respectively. Antegrade
wire escalation was used in 780 procedures (71.1%), and was the ﬁnal
successful crossing strategy in 463 procedures (59.3%). A total of 1630
guidewires (2.4  1.4 per procedure) were used for antegrade wire
escalation. The most frequently used guidewires were the Pilot 200
(Abbott Vascular, 24.7%), Fielder XT (Asahi Intecc, 19.7%), and the
Conﬁanza Pro 12 (Asahi Intecc, 12.6%) (Figure 1). The same guidewires
were the ones that most commonly led to successful CTO crossing:
Pilot 200 (35.2% of successful antegrade wire crossings), Fielder XT
(20%) and Conﬁanza Pro 12 (10.7%). A microcatheter or over-the-wire
balloon was used in 73.8% of antegrade wire escalation cases, as fol-
lows: Corsair (Asahi-Intecc, 42.8%), Finecross (Terumo, 18.6%), over-
the-wire balloon (14.2%), CrossBoss (Boston Scientiﬁc, 12.7%), and
Venture (St Jude Medical, 3.3%).CONCLUSIONS Our contemporary, multicenter CTO PCI registry demon-
strates remarkable consistency in guidewire selection for antegrade wire
escalation, with polymer-jacketed guidewires being used in most cases
including most successfully crossed cases. Upfront use of the Pilot 200
guidewire might offer the best chance for successful guidewire crossing.
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BACKGROUND The prevalence of native coronary CTO following cor-
onary artery bypass grafts (CABG) is high. At 10 years following CABG,
half patients will have at least one saphenous vein graft (SVG) occluded
and/or many SVGs will be diseased. Long-term outcome post SVG PCI is
poor, with high occlusion rate. If symptomatic, these patients may be
considered for a native coronary CTO PCI rather than SVG PCI. We
examined the feasibility and outcomes of CTO PCI using a patent or
occluded SVG as a retrograde conduit to the native CTO vessel.
METHODS Our preferred wire to cross an occluded SVG is Pilot 200
(Abbott Vascular, US) followed by amicrocatheter (MC) (usually Corsair,
Asahi Intecc, Japan), whereas standard workhorse wire can be used in
patent but diseased SVGs or arterial graft. MC tip injection is performed
to assess if the wire tracked the vein structure in case of an occluded
SVG. Clips and other surgical landmarks are used to track the occluded
graft with the wire. Once the MC is at the distal CTO cap, standard
techniques to open CTO are employed. We assessed the proportion of
patients treated with such technique from SVGs. We speciﬁcally
reviewed the J-CTO score, the prevalence of occluded vs. patent graft,
the type of graft crossed (SVG or arterial graft), technical success and
management of the graft after successful PCI of the native CTO.
RESULTS From 03.2009 to 04.2015 431 CTO PCI cases were performed
by a single operator (SR) or a teamof 2 operators (SR andCMN). Of these,
156 (36.2%) were done in post-CABG patients. In the post-CABG cohort,
an antegrade approach was used in 68 (43.6%) and a retrograde in 88
(56.4%) of cases. In the retrograde approach, septal collateral channels
(CCs) were used in 26 (29.5%), epicardial in 34 (38.6%) and SVGs in 28
(31.8%) of cases. Technical success of CTO revascularization in post-
CABG patients (J-CTO score 2.510.1) was 91%. In the sub-group treated
from an SVG,mean J-CTO score was 3.040.19. The CTO locationwas in
the right coronary artery in 43%, left circumﬂex in 43%, left anterior
descending in 7% and in the left main in 7%. When using an SVG, suc-
cess was achieved in 27 cases (96.4%). A total of 15 SVGs (53.6%) were
occluded before the retrograde attempt, and the oldest occlusion was
4-years old. Most common native coronary CTO recanalization
